BUZZ-Mangoceuticals to evaluate potential strategic alternatives, shares rise

Reuters10-22

** Shares of telehealth company Mangoceuticals , also known as MangoRx, rise 2.1% to $3.94 premarket

** Company says it has initiated a review process to evaluate potential strategic alternatives, including but not limited to potential mergers, acquisitions, divestitures and other transactions

** MGRX has not established a timeline for completion of the review process

** Earlier this week, Eli Lilly sued three medical spas and online vendors, including MangoRx, for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss drug Zepbound

** The lawsuit came after MangoRx launched its own brand called "Trim" — a compounded, oral dissolvable tirzepatide tablet

** Up to last close, stock down 41.5% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment